GENELUX Corp
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -56.7% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $4.36 | $2.36 | $14.01 | |
| P/S | 11131.8x | 24419.2x | 11131.8x | 2214.0x |
| P/B | 16.9x | 16.9x | 3.4x | 19.3x |
| EPS | -$0.86 | -$0.95 | -$1.16 | |
| Profit margin | -373362.50% | -401812.50% | -373362.50% | -16645.29% |
| ROE |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| QUCYQuantum Cyber N.V. | $1.42 | — | 1.7x | — | -212.53% | $119.38M |
| NTHINeonc Technologies Holdings Inc | $4.69 | — | — | — | — | $121.64M |
| JYNTJOINT Corp | $8.38 | 59.9x | 7.2x | — | 10.62% | $118.52M |
| ENGNenGene Therapeutics Inc. | $1.83 |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Company description provided by Yahoo Finance.
| -145.31% |
| -278.46% |
| -113.68% |
| -145.31% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.5x |
| — |
| -52.59% |
| $122.26M |
| ANIXAnixa Biosciences Inc | $3.48 | — | 8.1x | — | -71.97% | $118.4M |
| RANIRani Therapeutics Holdings, Inc. | $0.84 | — | 2.9x | — | -172.15% | $118.04M |